Recon: GSK acquires Sierra for $1.9B to boost drug pipeline; ICER says $2.1M price for Bluebird’s gene therapy is cost effective
ReconJoanne S. Eglovitch
Biologics/ biosimilars/ vaccinesBiotechnologyDiagnostics/IVDsGlobalMedical DevicesNorth AmericaPharmaceuticalsRegulatory Intelligence/Policy